Relative potency of prorenoate and spironolactone in normal man.
The potency of single doses of a new aldosterone antagonist, prorenoate, in reversing the renal effects of the synthetic mineralocorticoid fludrocortisone was compared to that of spironolactone in a double-blind balanced crossover study in 12 healthy subjects. The potency of prorenoate potassium as related to elevation of the urinary log 10 10 Na/K ratio (2.69:1) and as related to potassium retention (3.75:1) was significantly higher than that of spironolactone. Prorenoate produced greater natriuresis (1.64:1) but the difference was not significant. There was evidence for a qualitative difference between spironolactone and prorenoate; the latter significantly more potent in retaining potassium than in increasing sodium excretion. The simple methodology described is based on standard bioassay principles, yielded a valid and sensitive comparison of the two drugs, and should prove useful in the evaluation of other aldosterone antagonists.
D000293:Adolescent; D000328:Adult; D002191:Canrenoic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000652:urine; D004305:Dose-Response Relationship, Drug; D005438:Fludrocortisone / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists; D011188:Potassium / Q000652:urine; D011245:Pregnadienes / Q000494:pharmacology*; D012964:Sodium / Q000652:urine; D013148:Spironolactone / Q000009:adverse effects / Q000494:pharmacology* / Q000031:analogs & derivatives
D000451:Mineralocorticoid Receptor Antagonists; D011245:Pregnadienes; D013148:Spironolactone; D002191:Canrenoic Acid; D012964:Sodium; D003404:Creatinine; D011188:Potassium; C010768:prorenoate potassium; D005438:Fludrocortisone